The role of belataceptin transplantation: Results and implications of clinical trials in the context of other new biological immunosuppressant agents

Clinical Transplantation

Volumn 27, Issue 1, 2013, Pages

  Heemann, Uwe ^a   Viklicky, Ondrej ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Belatacept; Biologic agents; Immunosuppressive therapy; Renal transplantation; Survival

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CREATININE; CYCLOSPORIN A; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GLUCOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PHOSPHOLIPID ANTIBODY; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ANEMIA; ARTERY HYALINOSIS; CARDIOVASCULAR RISK; CHRONIC ALLOGRAFT NEPHROPATHY; COMORBIDITY; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYALINE DEGENERATION; HYPERTENSION; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE ATROPHY; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MORTALITY; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMALL ARTERY HYALINOSIS; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84873076795     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12044     Document Type: Review

References (77)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
2. Hariharan S, McBride MA, Cherikh WS et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002: 63: 311.
3. Fitzsimmons WE, Thompson D, Hariharan S et al. Serum creatinine as a surrogate endpoint for graft loss in kidney transplantation: validation efforts from multicentre trials. Am J Transplant 2002: 2(Suppl 3): 272 (Abstract #533).
4. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003: 75: 1291.
5. Pilmore H, Dent H, Chang S et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010: 89: 851.
6. Samaniego M, Becker BN, Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol 2006: 2: 688.
7. Pallet N, Legendre C. Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach. Pharmacogenomics 2010: 11: 1491.
8. Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008: 3: S56.
9. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
10. Etienne I, Toupance O, Benichou J et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrol Dial Transplant 2010: 25: 3096.
11. Gallagher M, Jardine M, Perkovic V et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009: 87: 1877.
12. Brouard S, Renaudin K, Soulillou JP. Revisiting the natural history of IF/TA in renal transplantation. Am J Transplant 2011: 11: 647.
13. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001: 72(6 Suppl): S9.
14. Artz MA, Boots JM, Ligtenberg G et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003: 14: 1880.
15. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004: 4: 937.
16. Hohage H, Welling U, Heck M et al. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors. Int Immunopharmacol 2005: 5: 117.
17. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003: 18(Suppl 1): i7.
18. Marcén R, Chahin J, Alarcon A et al. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc 2006: 38: 2427.
19. Margreiter R, Pohanka E, Sparacino V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl Int 2005: 18: 816.
20. Krämer BK, Boger C, Kruger B et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transpl Proc 2005: 37: 1868.
21. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007: 7: 1506.
22. Kamar N, Mariat C, Delahousse M et al. New onset diabetes mellitus incidence and risk factors in kidney transplantation: results of the observational cross-sectional study diapason. Transplant Proc 2006: 38: 2295.
23. Rodrigo E, Ruiz JC, Angeles de Cos M et al. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transpl Proc 2009: 41: 2328.
24. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diab Rep 2009: 9: 305.
25. Crutchlow MF, Bloom RD. Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2007: 2: 343.
26. Legendre C, Campistol JM, Squifflet JP et al. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 2003: 35: 151S.
27. Ekberg H, Bernasconi C, Noldeke J et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010: 25: 2004.
28. Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010: 73: 333.
29. Stratta RJ, Pietrangeli C, Baillie GM. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation. Pharmacotherapy 2010: 30: 144.
30. Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009: 54: 935.
31. Marks R, Finke J. Biologics in the prevention and treatment of graft rejection. Springer Semin Immunopathol 2006: 27: 457.
32. Hansel TT, Kropshofer H, Singer T et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010: 9: 325.
33. Glotz D, Charpentier B, Abramovicz D et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010: 89: 1511.
34. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003: 75: 844.
35. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007: 7: 560.
36. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
37. Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004: 78: 1332.
38. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007: 83: 883.
39. Vathsala A, Ona ET, Tan SY et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005: 80: 765.
40. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005: 200: 505.
41. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008: 22: 200.
42. Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005: 5: 2539.
43. Gabardi S, Martin ST, Roberts KL et al. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm 2011: 68: 211.
44. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005: 5: 443.
45. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010: 10: 547.
46. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005: 353: 770.
47. Rostaing L, Massari P, Garcia VD et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011: 6: 430.
48. Ferguson R, Grinyó J, Vincenti F et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011: 11: 66.
49. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010: 10: 535.
50. Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT: a Phase III study of belatacept vs cyclosporine in kidney transplant recipients. Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 227), 2011.
51. Durrbach A, Citterio F, Mulloy L et al. Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies. Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 230), 2011.
52. Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010: 21: 1587.
53. Larsen CP, Grinyo J, Medina-Pestana J et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010: 90: 1528.
54. Florman S, Becker T, Bresnahan B et al. Three-year outcomes by donor type in Phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT). Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 229), 2011.
55. Larsen C, Grinyo J, Medina Pestana J et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies. Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 228), 2011.
56. Grinyó J, Charpentier B, Pestana JM et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010: 90: 1521.
57. Vanrenterghem Y, Bresnahan B, Campistol J et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011: 91: 976.
58. Imai A, Suzuki T, Sugitani A et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007: 84: 1020.
59. Aoyagi T, Yamashita K, Suzuki T et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009: 9: 1732.
60. Haanstra KG, Ringers J, Sick EA et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003: 75: 637.
61. Pearson TC, Trambley J, Odom K et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002: 74: 933.
62. Song L, Ma A, Dun H et al. A novel fully human anti-CD40 monoclonal antibody, ASKP1240, mono- and combination-therapy in prolongation of renal allograft survival in cynomolgus monkeys. Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 1401), 2011.
63. Wang H, Baroja M, Lan Z et al. Combination of novel anti-CD45RB and anti-CD40 chimeric antibodies prolongs renal allograft survival in cynomolgus monkeys. Presented at the American Transplant Congress, Philadelphia, PA, USA (Abstract 1537.5), 2011.
64. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003: 48: 719.
65. Goldstein DR. T cell costimulation blockade and organ transplantation: a change of philosophy for transplant immunologists? J Immunol 2011: 186: 2691.
66. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol Mech Dis 2008: 3: 220.
67. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009: 9: 231.
68. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010: 362: 1744.
69. Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010: 362: 1746.
70. Nester C, Stewart Z, Myers D et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011: 6: 1488.
71. Weitz M, Amon O, Bassler D et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011: 26: 1325.
72. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009: 360: 542.
73. Lo DJ, Weaver TA, Stempora L et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011: 11: 22.
74. Salek-Ardakani S, Flynn R, Arens R et al. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest 2011: 121: 296.
75. Han SL, Yu LX, Ma JJ et al. Effect of anti-tumor necrosis factor-alpha monoclonal antibody in alleviating renal ischemia-reperfusion injury. Di Yi Jun Yi Da Xue Xue Bao 2003: 23: 332.
76. Daemen MA, van de Ven MW, Heineman E et al. Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury. Transplantation 1999: 67: 792.
77. Lei J, He F, Wu M et al. Administration of anti-interleukin-6 monoclonal antibody prolongs cardiac allograft survival. Transpl Int 2010: 23: 1271.